HighTower Advisors’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-9,769
| Closed | -$213K | – | 4004 |
|
|
2026
Q1 | $213K | Buy |
+9,769
| New | +$189K | ﹤0.01% | 3439 |
|
|
2025
Q4 | – | Sell |
-29,977
| Closed | -$578K | – | 3947 |
|
|
2025
Q3 | $578K | Sell |
29,977
-12,347
| -29% | -$220K | ﹤0.01% | 2497 |
|
|
2025
Q2 | $724K | Buy |
42,324
+4,727
| +13% | +$202K | ﹤0.01% | 2237 |
|
|
2025
Q1 | $2.4M | Buy |
37,597
+823
| +2% | +$86.6K | ﹤0.01% | 1434 |
|
|
2024
Q4 | $4.47M | Sell |
36,774
-2,559
| -7% | -$314K | 0.01% | 1095 |
|
|
2024
Q3 | $4.87M | Sell |
39,333
-10,327
| -21% | -$1.43M | 0.01% | 1044 |
|
|
2024
Q2 | $7.86M | Buy |
49,660
+14,366
| +41% | +$1.85M | 0.01% | 811 |
|
|
2024
Q1 | $4.56M | Sell |
35,294
-777
| -2% | -$95.2K | 0.01% | 1010 |
|
|
2023
Q4 | $3.48M | Buy |
36,071
+4,122
| +13% | +$395K | 0.01% | 1146 |
|
|
2023
Q3 | $3.86M | Sell |
31,949
-31
| -0.1% | -$3.5K | 0.01% | 1039 |
|
|
2023
Q2 | $3.66M | Sell |
31,980
-5,557
| -15% | -$717K | 0.01% | 1047 |
|
|
2023
Q1 | $5.18M | Sell |
37,537
-632
| -2% | -$82K | 0.01% | 840 |
|
|
2022
Q4 | $4.94M | Sell |
38,169
-263
| -0.7% | -$30.5K | 0.01% | 862 |
|
|
2022
Q3 | $4.25M | Sell |
38,432
-12,433
| -24% | -$1.25M | 0.01% | 866 |
|
|
2022
Q2 | $3.79M | Buy |
50,865
+11,880
| +30% | +$874K | 0.01% | 939 |
|
|
2022
Q1 | $3.06M | Sell |
38,985
-78
| -0.2% | -$5.97K | 0.01% | 1131 |
|
|
2021
Q4 | $3.53M | Sell |
39,063
-1,364
| -3% | -$117K | 0.01% | 1075 |
|
|
2021
Q3 | $3.73M | Buy |
40,427
+41
| +0.1% | +$3.16K | 0.01% | 944 |
|
|
2021
Q2 | $3.15M | Buy |
40,386
+6,577
| +19% | +$499K | 0.01% | 985 |
|
|
2021
Q1 | $2.52M | Buy |
33,809
+2,270
| +7% | +$209K | 0.01% | 1014 |
|
|
2020
Q4 | $5.38M | Buy |
31,539
+3,271
| +12% | +$485K | 0.02% | 565 |
|
|
2020
Q3 | $3.97M | Sell |
28,268
-562
| -2% | -$85.4K | 0.02% | 634 |
|
|
2020
Q2 | $4.61M | Sell |
28,830
-1,193
| -4% | -$162K | 0.03% | 535 |
|
|
2020
Q1 | $2.94M | Sell |
30,023
-283
| -0.9% | -$32.3K | 0.02% | 615 |
|
|
2019
Q4 | $3.91M | Sell |
30,306
-1,672
| -5% | -$169K | 0.02% | 638 |
|
|
2019
Q3 | $2.42M | Sell |
31,978
-2,956
| -8% | -$349K | 0.01% | 830 |
|
|
2019
Q2 | $5.31M | Sell |
34,934
-5,659
| -14% | -$688K | 0.03% | 520 |
|
|
2019
Q1 | $4.84M | Sell |
40,593
-3,721
| -8% | -$478K | 0.03% | 509 |
|
|
2018
Q4 | $4.83M | Sell |
44,314
-4,210
| -9% | -$527K | 0.04% | 464 |
|
|
2018
Q3 | $7.83M | Sell |
48,524
-552
| -1% | -$75.5K | 0.06% | 362 |
|
|
2018
Q2 | $6.49M | Sell |
49,076
-9,884
| -17% | -$932K | 0.05% | 408 |
|
|
2018
Q1 | $4.37M | Sell |
58,960
-9,558
| -14% | -$637K | 0.04% | 508 |
|
|
2017
Q4 | $3.82M | Sell |
68,518
-1,078
| -2% | -$57.1K | 0.03% | 584 |
|
|
2017
Q3 | $3.17M | Buy |
69,596
+16,119
| +30% | +$644K | 0.03% | 649 |
|
|
2017
Q2 | $1.8M | Buy |
53,477
+6,902
| +15% | +$225K | 0.02% | 841 |
|
|
2017
Q1 | $1.38M | Buy |
46,575
+5,225
| +13% | +$162K | 0.01% | 893 |
|
|
2016
Q4 | $1.13M | Buy |
41,350
+10,540
| +34% | +$423K | 0.01% | 920 |
|
|
2016
Q3 | $1.89M | Sell |
30,810
-8,147
| -21% | -$246K | 0.02% | 675 |
|
|
2016
Q2 | $747K | Buy |
38,957
+21,303
| +121% | +$395K | 0.01% | 993 |
|
|
2016
Q1 | $345K | Buy |
+17,654
| New | +$308K | ﹤0.01% | 1553 |
|
Other funds holding SRPT
EAM
HighTower Advisors's SRPT Position: Q2 2026 in Review
HighTower Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 9,769 shares — an estimated $213K sold.
HighTower Advisors first reported a position in SRPT in Q1 2016 and held it in 40 quarters. The position peaked at $7.86M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- HighTower Advisors reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
- HighTower Advisors sold 9,769 Sarepta Therapeutics shares in Q2 2026, an estimated $213K.
- HighTower Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 40 quarters.
- HighTower Advisors's Sarepta Therapeutics position peaked at $7.86M in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.